An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects
Latest Information Update: 02 Nov 2021
Price :
$35 *
At a glance
- Drugs Tasurgratinib (Primary) ; Rabeprazole; Rifampicin
- Indications Breast cancer; Cholangiocarcinoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Co Ltd
- 29 Oct 2021 Status changed from active, no longer recruiting to completed.
- 29 Jun 2021 Planned End Date changed from 31 Jan 2022 to 1 Oct 2021.
- 29 Jun 2021 Status changed from not yet recruiting to active, no longer recruiting.